--- title: "Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Wedbush" type: "News" locale: "en" url: "https://longbridge.com/en/news/300031615.md" description: "Wedbush initiated coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with an 'outperform' rating and a $17.00 price target, indicating significant upside. Other firms like Oppenheimer also set 'outperform' ratings, while Wall Street Zen downgraded to 'sell'. The consensus rating is 'Moderate Buy' with a $17.80 target. Recent analyst reports highlight mixed views, though institutional investors increased holdings in Q2." datetime: "2026-09-24T12:42:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300031615.md) - [en](https://longbridge.com/en/news/300031615.md) - [zh-HK](https://longbridge.com/zh-HK/news/300031615.md) generator: "portal-rs" --- # Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Wedbush Wedbush started coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) in a note issued to investors on Thursday, Benzinga reports. The firm set an "outperform" rating and a $17.00 price target on the stock. Wedbush's target price indicates a potential upside of 108.85% from the stock's current price. Other research analysts have also issued reports about the company. Oppenheimer started coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They set an "outperform" rating and a $17.00 price target on the stock. Wall Street Zen raised shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 12th. Stifel Nicolaus set a $25.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.80. **Get Our Latest Stock Report on EPRX** ## Eupraxia Pharmaceuticals Stock Down 5.1% EPRX stock opened at $8.14 on Thursday. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals has a fifty-two week low of $5.16 and a fifty-two week high of $9.32. The firm's 50-day simple moving average is $7.11 and its 200 day simple moving average is $7.00. The stock has a market cap of $529.25 million, a PE ratio of -7.98 and a beta of 1.07. Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. As a group, sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year. ## Hedge Funds Weigh In On Eupraxia Pharmaceuticals Institutional investors have recently bought and sold shares of the stock. AXQ Capital LP boosted its holdings in shares of Eupraxia Pharmaceuticals by 34.2% in the second quarter. AXQ Capital LP now owns 21,150 shares of the company's stock worth $140,000 after buying an additional 5,390 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Eupraxia Pharmaceuticals during the 2nd quarter worth about $4,037,289. Bank of America Corp DE acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $1,750,000. Jupiter Topco LLC purchased a new position in Eupraxia Pharmaceuticals during the second quarter valued at approximately $6,851,000. Finally, Cibc World Market Inc. purchased a new stake in Eupraxia Pharmaceuticals in the 2nd quarter worth approximately $1,539,000. ## About Eupraxia Pharmaceuticals (Get Free Report) Eupraxia Pharmaceuticals Inc NASDAQ: EPRX is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients' exposure to medication throughout the body. Eupraxia's development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects. The company's lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee. ## Read More - Five stocks we like better than Eupraxia Pharmaceuticals - Can Marvell Keep Up in the Custom AI Chip Race? - DraftKings Falls 7.6%: Is Kalshi's NFL Lead Really That Big? - Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch? - Chips to Bots: Qualcomm’s Agentic AI Breakout *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Eupraxia Pharmaceuticals Right Now? Before you consider Eupraxia Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list. While Eupraxia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ### Related Stocks - [EPRX.US](https://longbridge.com/en/quote/EPRX.US.md) - [OPY.US](https://longbridge.com/en/quote/OPY.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [CM.US](https://longbridge.com/en/quote/CM.US.md) - [MRVL.US](https://longbridge.com/en/quote/MRVL.US.md) - [DKNG.US](https://longbridge.com/en/quote/DKNG.US.md) - [TTWO.US](https://longbridge.com/en/quote/TTWO.US.md) - [QCOM.US](https://longbridge.com/en/quote/QCOM.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data](https://longbridge.com/en/news/300568655.md) - [HC Wainwright & Co. reiterates Buy rating on Eupraxia Pharmaceuticals, $11 price target](https://longbridge.com/en/news/300671439.md) - [PRECIOUS-Gold inches higher as softer US inflation dims October Fed hike bets](https://longbridge.com/en/news/300644169.md) - [Tesla Sell Ratings Slide as Analysts Bet on Musk's AI Ambitions Coming up Trumps](https://longbridge.com/en/news/300678162.md) - [BUZZ-Street View: Argon revives Google's AI standing, but questions remain](https://longbridge.com/en/news/300699265.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**